Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Revisiting the role of surgery in the treatment of Graves' disease

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Harvard

Cohen, O, Ronen, O, Khafif, A, Rodrigo, JP, Simo, R, Pace-Asciak, P, Randolph, G, Mikkelsen, LH, Kowalski, LP, Olsen, KD, Sanabria, A, Tufano, RP, Babighian, S, Shaha, AR, Zafereo, M & Ferlito, A 2022, 'Revisiting the role of surgery in the treatment of Graves' disease', Clinical Endocrinology, bind 96, nr. 6, s. 747-757. https://doi.org/10.1111/cen.14653

APA

Cohen, O., Ronen, O., Khafif, A., Rodrigo, J. P., Simo, R., Pace-Asciak, P., Randolph, G., Mikkelsen, L. H., Kowalski, L. P., Olsen, K. D., Sanabria, A., Tufano, R. P., Babighian, S., Shaha, A. R., Zafereo, M., & Ferlito, A. (2022). Revisiting the role of surgery in the treatment of Graves' disease. Clinical Endocrinology, 96(6), 747-757. https://doi.org/10.1111/cen.14653

CBE

Cohen O, Ronen O, Khafif A, Rodrigo JP, Simo R, Pace-Asciak P, Randolph G, Mikkelsen LH, Kowalski LP, Olsen KD, Sanabria A, Tufano RP, Babighian S, Shaha AR, Zafereo M, Ferlito A. 2022. Revisiting the role of surgery in the treatment of Graves' disease. Clinical Endocrinology. 96(6):747-757. https://doi.org/10.1111/cen.14653

MLA

Vancouver

Cohen O, Ronen O, Khafif A, Rodrigo JP, Simo R, Pace-Asciak P o.a. Revisiting the role of surgery in the treatment of Graves' disease. Clinical Endocrinology. 2022 jun.;96(6):747-757. https://doi.org/10.1111/cen.14653

Author

Cohen, Oded ; Ronen, Ohad ; Khafif, Avi ; Rodrigo, Juan P ; Simo, Ricard ; Pace-Asciak, Pia ; Randolph, Gregory ; Mikkelsen, Lauge H ; Kowalski, Luiz P ; Olsen, Kerry D ; Sanabria, Alvaro ; Tufano, Ralph P ; Babighian, Silvia ; Shaha, Ashok R ; Zafereo, Mark ; Ferlito, Alfio. / Revisiting the role of surgery in the treatment of Graves' disease. I: Clinical Endocrinology. 2022 ; Bind 96, Nr. 6. s. 747-757.

Bibtex

@article{443f911bf47942ceac48dd78b087c027,
title = "Revisiting the role of surgery in the treatment of Graves' disease",
abstract = "Graves' disease (GD) can be managed by antithyroid drugs (ATD), radioactive iodine (RAI) and surgery. Thyroidectomy offers the highest success rates for both primary and persistent disease, yet it is the least recommended or utilized option reaching <1% for primary disease and <25% for persistent disease. Several surveys have found surgery to be the least recommended by endocrinologists worldwide. With the development of remote access thyroidectomies and intraoperative nerve monitoring of the recurrent laryngeal nerve, combined with current knowledge of possible risks associated with RAI or failure of ATDs, revaluation of the benefit to harm ratio of surgery in the treatment of GD is warranted. The aim of this review is to discuss possible reasons for the low proportion of surgery in the treatment of GD, emphasizing an evidence-based approach to the clinicians' preferences for surgical referrals, surgical indications and confronting traditional reasons and concerns relating to the low referral rate with up-to-date data.",
keywords = "Antithyroid Agents/therapeutic use, Graves Disease/drug therapy, Humans, Iodine Radioisotopes/therapeutic use, Thyroid Neoplasms/surgery, Thyroidectomy",
author = "Oded Cohen and Ohad Ronen and Avi Khafif and Rodrigo, {Juan P} and Ricard Simo and Pia Pace-Asciak and Gregory Randolph and Mikkelsen, {Lauge H} and Kowalski, {Luiz P} and Olsen, {Kerry D} and Alvaro Sanabria and Tufano, {Ralph P} and Silvia Babighian and Shaha, {Ashok R} and Mark Zafereo and Alfio Ferlito",
note = "{\textcopyright} 2021 John Wiley & Sons Ltd.",
year = "2022",
month = jun,
doi = "10.1111/cen.14653",
language = "English",
volume = "96",
pages = "747--757",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "6",

}

RIS

TY - JOUR

T1 - Revisiting the role of surgery in the treatment of Graves' disease

AU - Cohen, Oded

AU - Ronen, Ohad

AU - Khafif, Avi

AU - Rodrigo, Juan P

AU - Simo, Ricard

AU - Pace-Asciak, Pia

AU - Randolph, Gregory

AU - Mikkelsen, Lauge H

AU - Kowalski, Luiz P

AU - Olsen, Kerry D

AU - Sanabria, Alvaro

AU - Tufano, Ralph P

AU - Babighian, Silvia

AU - Shaha, Ashok R

AU - Zafereo, Mark

AU - Ferlito, Alfio

N1 - © 2021 John Wiley & Sons Ltd.

PY - 2022/6

Y1 - 2022/6

N2 - Graves' disease (GD) can be managed by antithyroid drugs (ATD), radioactive iodine (RAI) and surgery. Thyroidectomy offers the highest success rates for both primary and persistent disease, yet it is the least recommended or utilized option reaching <1% for primary disease and <25% for persistent disease. Several surveys have found surgery to be the least recommended by endocrinologists worldwide. With the development of remote access thyroidectomies and intraoperative nerve monitoring of the recurrent laryngeal nerve, combined with current knowledge of possible risks associated with RAI or failure of ATDs, revaluation of the benefit to harm ratio of surgery in the treatment of GD is warranted. The aim of this review is to discuss possible reasons for the low proportion of surgery in the treatment of GD, emphasizing an evidence-based approach to the clinicians' preferences for surgical referrals, surgical indications and confronting traditional reasons and concerns relating to the low referral rate with up-to-date data.

AB - Graves' disease (GD) can be managed by antithyroid drugs (ATD), radioactive iodine (RAI) and surgery. Thyroidectomy offers the highest success rates for both primary and persistent disease, yet it is the least recommended or utilized option reaching <1% for primary disease and <25% for persistent disease. Several surveys have found surgery to be the least recommended by endocrinologists worldwide. With the development of remote access thyroidectomies and intraoperative nerve monitoring of the recurrent laryngeal nerve, combined with current knowledge of possible risks associated with RAI or failure of ATDs, revaluation of the benefit to harm ratio of surgery in the treatment of GD is warranted. The aim of this review is to discuss possible reasons for the low proportion of surgery in the treatment of GD, emphasizing an evidence-based approach to the clinicians' preferences for surgical referrals, surgical indications and confronting traditional reasons and concerns relating to the low referral rate with up-to-date data.

KW - Antithyroid Agents/therapeutic use

KW - Graves Disease/drug therapy

KW - Humans

KW - Iodine Radioisotopes/therapeutic use

KW - Thyroid Neoplasms/surgery

KW - Thyroidectomy

UR - http://www.scopus.com/inward/record.url?scp=85121735496&partnerID=8YFLogxK

U2 - 10.1111/cen.14653

DO - 10.1111/cen.14653

M3 - Review

C2 - 34954838

VL - 96

SP - 747

EP - 757

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 6

ER -

ID: 78048918